Rhizomelic PseudopolyarthritisSymptoms, Doctors, Treatments, Advances & More
Learn About Rhizomelic Pseudopolyarthritis
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
OSF Medical Group - Rheumatology
Imran Umer is an Internal Medicine specialist and a Rheumatologist practicing medicine in Peoria, Illinois. Dr. Umer is rated as a Distinguished provider by MediFind in the treatment of Rhizomelic Pseudopolyarthritis. He is also highly rated in 32 other conditions, according to our data. His clinical expertise encompasses Polymyalgia Rheumatica, Rhizomelic Pseudopolyarthritis, Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), and Tissue Biopsy. Dr. Umer is board certified in American Board Of Internal Medicine.
Rheumatology At Village Pointe Health Center
Michael Feely is a Rheumatologist practicing medicine in Omaha, Nebraska. He has been practicing medicine for over 22 years. Dr. Feely is rated as a Distinguished provider by MediFind in the treatment of Rhizomelic Pseudopolyarthritis. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Polymyalgia Rheumatica, Rhizomelic Pseudopolyarthritis, Rheumatoid Arthritis (RA), and Necrotizing Vasculitis.
Bassett Medical Center
David Griger is a Rheumatologist practicing medicine in Cooperstown, New York. Dr. Griger is rated as a Distinguished provider by MediFind in the treatment of Rhizomelic Pseudopolyarthritis. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Paget's Disease of Bone, Rheumatoid Arthritis (RA), Polymyalgia Rheumatica, and Rhizomelic Pseudopolyarthritis.
Summary: Polymyalgia rheumatic (PMR) is an inflammatory rheumatic disease affecting the elderly. The diagnosis is based on established ACR/EULAR classification criteria. The activity of the disease is evaluated using the PMR-AS, a disease activity score based on morning stiffness, ability to elevate the upper limbs, physician's global disease assessment and pain assessment measured by the patient using VAS...
Summary: This is a randomized, double-blind, placebo-controlled, parallel-group, Phase 4, 3-group study to assess whether treatment with sarilumab at either 150 mg q2w (once every two weeks) or at 200 mg q2w, each given with a 52-week prednisone taper, is superior to placebo given with a 52-week prednisone taper in participants with early polymyalgia rheumatica (PMR) and to determine the safety and tolerab...